WO2002080969A1 - Remedies for infant chronic arthritis-relating diseases - Google Patents

Remedies for infant chronic arthritis-relating diseases Download PDF

Info

Publication number: WO2002080969A1
Authority: WO; WIPO (PCT)
Prior art keywords: remedies; chronic arthritis; infant; infant chronic; relating diseases
Prior art date: 2001-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

PCT/JP2002/003312

Other languages

English (en)

French (fr)

Inventor

Kazuyuki Yoshizaki

Norihiro Nishimoto

Masahiro Iwamoto

Seiji Minota

Shumpei Yokota

Takako Miyamae

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chugai Pharmaceutical Co Ltd

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-02

Filing date

2002-04-02

Publication date

2002-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26612973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002080969(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-04 Priority to UA2003109818A priority Critical patent/UA80091C2/uk

2002-04-02 Priority to MXPA03008955A priority patent/MXPA03008955A/es

2002-04-02 Priority to US10/473,165 priority patent/US20040115197A1/en

2002-04-02 Priority to HU0303952A priority patent/HU230197B1/hu

2002-04-02 Priority to AU2002243032A priority patent/AU2002243032B2/en

2002-04-02 Priority to IL15807902A priority patent/IL158079A0/xx

2002-04-02 Priority to PL365339A priority patent/PL216534B1/pl

2002-04-02 Priority to BR0208636-0A priority patent/BR0208636A/pt

2002-04-02 Priority to HK04105346.6A priority patent/HK1062408B/xx

2002-04-02 Priority to NZ528479A priority patent/NZ528479A/en

2002-04-02 Priority to EP19196253.9A priority patent/EP3640261A1/en

2002-04-02 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2002-04-02 Priority to CA2443294A priority patent/CA2443294C/en

2002-04-02 Priority to EP02708772A priority patent/EP1374900A4/en

2002-04-02 Priority to JP2002579008A priority patent/JP3702274B2/ja

2002-04-02 Priority to KR1020037012661A priority patent/KR100842133B1/ko

2002-10-17 Publication of WO2002080969A1 publication Critical patent/WO2002080969A1/ja

2003-09-24 Priority to IL158079A priority patent/IL158079A/en

2003-10-01 Priority to NO20034388A priority patent/NO20034388L/no

2003-10-02 Anticipated expiration legal-status Critical

2007-02-09 Priority to US11/704,233 priority patent/US7955598B2/en

2007-11-25 Priority to IL187604A priority patent/IL187604A/en

2011-04-28 Priority to US13/064,953 priority patent/US9255145B2/en

2016-01-04 Priority to US14/986,884 priority patent/US20160194401A1/en

2018-04-06 Priority to US15/946,866 priority patent/US20180222988A1/en

Status Ceased legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PCT/JP2002/003312 2001-04-02 2002-04-02 Remedies for infant chronic arthritis-relating diseases Ceased WO2002080969A1 (en)

Priority Applications (22)

Application Number	Priority Date	Filing Date	Title
UA2003109818A UA80091C2 (en)	2001-04-02	2002-02-04	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP2002579008A JP3702274B2 (ja)	2001-04-02	2002-04-02	小児慢性関節炎関連疾患治療剤
EP02708772A EP1374900A4 (en)	2001-04-02	2002-04-02	MEDICINE FOR TREATING DISEASES RELATED TO CHRONIC ARTHRITIS IN INFANT CHILDREN
HU0303952A HU230197B1 (hu)	2001-04-02	2002-04-02	Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
AU2002243032A AU2002243032B2 (en)	2001-04-02	2002-04-02	Remdies for infant chronic arthritis-relating diseases
IL15807902A IL158079A0 (en)	2001-04-02	2002-04-02	Pharmaceutical compositions containing an interleukin-6 antagonist
PL365339A PL216534B1 (pl)	2001-04-02	2002-04-02	Środek terapeutyczny do leczenia młodzieńczego reumatoidalnego zapalenia stawów o początku układowym i środek terapeutyczny do leczenia choroby Stilla wieku dorosłego
BR0208636-0A BR0208636A (pt)	2001-04-02	2002-04-02	Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com infncia
US10/473,165 US20040115197A1 (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases
NZ528479A NZ528479A (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases
EP19196253.9A EP3640261A1 (en)	2001-04-02	2002-04-02	Therapeutic agent for chronic arthritides diseases of childhood-related diseases
MXPA03008955A MXPA03008955A (es)	2001-04-02	2002-04-02	Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
CA2443294A CA2443294C (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases
KR1020037012661A KR100842133B1 (ko)	2001-04-02	2002-04-02	소아 만성 관절염 관련질환 치료제
HK04105346.6A HK1062408B (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases
IL158079A IL158079A (en)	2001-04-02	2003-09-24	Pharmaceutical preparations containing interleukin-6 antagonist
NO20034388A NO20034388L (no)	2001-04-02	2003-10-01	Terapeutisk middel for kronisk artritt sykdommer i barne- relaterte sykdommer
US11/704,233 US7955598B2 (en)	2001-04-02	2007-02-09	Therapeutic agent for chronic arthritides diseases of childhood-related diseases
IL187604A IL187604A (en)	2001-04-02	2007-11-25	Pharmaceuticals containing interlockin antagonist - 6 for the treatment of sitel disease
US13/064,953 US9255145B2 (en)	2001-04-02	2011-04-28	Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US14/986,884 US20160194401A1 (en)	2001-04-02	2016-01-04	Therapeutic agent for chronic arthritides diseases of childhood-related diseases
US15/946,866 US20180222988A1 (en)	2001-04-02	2018-04-06	Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2001-103627		2001-04-02
JP2001103627		2001-04-02
JP2001109131		2001-04-06
JP2001-109131		2001-04-06

Related Child Applications (3)

Application Number	Title	Priority Date	Filing Date
US10473165 A-371-Of-International		2002-04-02
US10/473,165 A-371-Of-International US20040115197A1 (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases
US11/704,233 Division US7955598B2 (en)	2001-04-02	2007-02-09	Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Publications (1)

Publication Number	Publication Date
WO2002080969A1 true WO2002080969A1 (en)	2002-10-17

Family

ID=26612973

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/003312 Ceased WO2002080969A1 (en)	2001-04-02	2002-04-02	Remedies for infant chronic arthritis-relating diseases

Country Status (17)

Country	Link
US (5)	US20040115197A1 (ja)
EP (4)	EP1972638A1 (ja)
JP (5)	JP3702274B2 (ja)
KR (2)	KR100842132B1 (ja)
CN (1)	CN100562339C (ja)
AU (1)	AU2002243032B2 (ja)
BR (1)	BR0208636A (ja)
CA (1)	CA2443294C (ja)
HU (1)	HU230197B1 (ja)
IL (3)	IL158079A0 (ja)
MX (1)	MXPA03008955A (ja)
NO (1)	NO20034388L (ja)
NZ (1)	NZ528479A (ja)
PL (1)	PL216534B1 (ja)
RU (2)	RU2541165C2 (ja)
UA (1)	UA80091C2 (ja)
WO (1)	WO2002080969A1 (ja)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007525524A (ja) *	2004-02-26	2007-09-06	ベイラー・リサーチ・インスチチユート	関節炎の全身処置のための組成物および方法
WO2008078715A1 (ja) *	2006-12-27	2008-07-03	Chugai Seiyaku Kabushiki Kaisha	Ｉｌ－６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US7919095B2 (en)	2006-08-03	2011-04-05	Vaccinex, Inc.	Anti-IL-6 monoclonal antibodies
EP2368577A2 (en)	2003-04-28	2011-09-28	Chugai Seiyaku Kabushiki Kaisha	Methods for treating interleukin-6 related diseases
WO2011149046A1 (ja)	2010-05-28	2011-12-01	独立行政法人国立がん研究センター	膵癌治療剤
WO2011149051A1 (ja)	2010-05-28	2011-12-01	中外製薬株式会社	抗腫瘍t細胞応答増強剤
WO2013176471A1 (ko)	2012-05-21	2013-11-28	한국생명공학연구원	곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
CN103739669A (zh) *	2013-12-31	2014-04-23	罗瑞雪	一种抑制白介素-6多肽及其应用
US8945558B2 (en)	2005-10-21	2015-02-03	Chugai Seiyaku Kabushiki Kaisha	Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US9260516B2 (en)	2006-04-07	2016-02-16	Osaka University	Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9725514B2 (en)	2007-01-23	2017-08-08	Shinshu University	Chronic rejection inhibitor
US10662245B2 (en)	2008-09-26	2020-05-26	Chugai Seiyaku Kabushiki Kaisha	Methods of reducing IL-6 activity for disease treatment
US10697883B2 (en)	2015-05-19	2020-06-30	National Center Of Neurology And Psychiatry	Method for determining application of therapy to multiple sclerosis (MS) patient
US10717781B2 (en)	2008-06-05	2020-07-21	National Cancer Center	Neuroinvasion inhibitor
US10774148B2 (en)	2015-02-27	2020-09-15	Chugai Seiyaku Kabushiki Kaisha	Composition for treating IL-6-related diseases
US10782290B2 (en)	2013-06-11	2020-09-22	National Center Of Neurology And Psychiatry	Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
US11046784B2 (en)	2006-03-31	2021-06-29	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
US11174317B2 (en)	2015-06-04	2021-11-16	National Center Of Neurology And Psychiatry	Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US11248053B2 (en)	2007-09-26	2022-02-15	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11332533B2 (en)	2007-09-26	2022-05-17	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
US11359194B2 (en)	2008-04-11	2022-06-14	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11692037B2 (en)	2017-10-20	2023-07-04	Hyogo College Of Medicine	Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891434B2 (en)	2010-11-30	2024-02-06	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8017121B2 (en) *	1994-06-30	2011-09-13	Chugai Seiyaku Kabushika Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1996012503A1 (en) *	1994-10-21	1996-05-02	Chugai Seiyaku Kabushiki Kaisha	Remedy for diseases caused by il-6 production
AU736282B2 (en)	1997-03-21	2001-07-26	Chugai Seiyaku Kabushiki Kaisha	A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20020187150A1 (en) *	1997-08-15	2002-12-12	Chugai Seiyaku Kabushiki Kaisha	Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1074268E (pt) *	1998-03-17	2008-02-28	Chugai Pharmaceutical Co Ltd	Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
JP4889187B2 (ja) *	2000-10-27	2012-03-07	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
UA80091C2 (en) *	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003068259A1 (fr) *	2002-02-14	2003-08-21	Chugai Seiyaku Kabushiki Kaisha	Produits pharmaceutiques en solution contenant des anticorps
EP1690550B1 (en) *	2003-10-17	2012-08-08	Chugai Seiyaku Kabushiki Kaisha	Therapeutic agent for mesothelioma
US8617550B2 (en) *	2003-12-19	2013-12-31	Chugai Seiyaku Kabushiki Kaisha	Treatment of vasculitis with IL-6 antagonist
JPWO2005090405A1 (ja)	2004-03-24	2008-04-17	中外製薬株式会社	インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es)	2004-03-24	2006-04-19	Chugai Pharmaceutical Co Ltd	Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JP5620626B2 (ja)	2005-03-31	2014-11-05	中外製薬株式会社	会合制御によるポリペプチド製造方法
WO2007074880A1 (ja) *	2005-12-28	2007-07-05	Chugai Seiyaku Kabushiki Kaisha	抗体含有安定化製剤
EP2009101B1 (en)	2006-03-31	2017-10-25	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
CA2652976C (en)	2006-06-02	2015-08-11	Regeneron Pharmaceuticals, Inc.	High affinity antibodies to human il-6 receptor
US8080248B2 (en) *	2006-06-02	2011-12-20	Regeneron Pharmaceuticals, Inc.	Method of treating rheumatoid arthritis with an IL-6R antibody
ES2721753T3 (es)	2007-05-21	2019-08-05	Alderbio Holdings Llc	Anticuerpos contra IL-6 y usos de los mismos
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en)	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US20090238825A1 (en) *	2007-05-21	2009-09-24	Kovacevich Brian R	Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en) *	2007-05-21	2012-08-28	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en)	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
MX343879B (es) *	2007-05-21	2016-11-25	Alderbio Holdings Llc	Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
US9701747B2 (en)	2007-05-21	2017-07-11	Alderbio Holdings Llc	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8404235B2 (en)	2007-05-21	2013-03-26	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
MX337081B (es)	2007-12-05	2016-02-10	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-nr10 y su uso.
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
US8034344B2 (en)	2008-05-13	2011-10-11	Novimmune S.A.	Anti-IL-6/IL-6R antibodies and methods of use thereof
US8420089B2 (en)	2008-11-25	2013-04-16	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en)	2008-11-25	2012-12-25	Alderbio Holdings Llc	Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US9212223B2 (en)	2008-11-25	2015-12-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) *	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en)	2008-11-25	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of arthritis
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
TWI646193B (zh)	2009-03-19	2019-01-01	中外製藥股份有限公司	抗體恆定區域改變體
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
MX2011012136A (es)	2009-05-15	2012-04-10	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-axl.
WO2011066371A2 (en)	2009-11-24	2011-06-03	Alder Biopharmaceuticals, Inc.	Antibodies to il-6 and use thereof
JP5837821B2 (ja)	2009-09-24	2015-12-24	中外製薬株式会社	抗体定常領域改変体
HUE033758T2 (en)	2009-10-26	2017-12-28	Hoffmann La Roche	A method for producing glycosylated immunoglobulin
US9775921B2 (en)	2009-11-24	2017-10-03	Alderbio Holdings Llc	Subcutaneously administrable composition containing anti-IL-6 antibody
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2543730B1 (en)	2010-03-04	2018-10-31	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
EP4029881A1 (en)	2010-11-08	2022-07-20	F. Hoffmann-La Roche AG	Subcutaneously administered anti-il-6 receptor antibody
WO2012071561A2 (en)	2010-11-23	2012-05-31	Alder Biopharmaceuticals, Inc.	Anti-il-6 antibodies for the treatment of anemia
HRP20180959T1 (hr)	2011-01-28	2018-07-27	Sanofi Biotechnology	Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
BR112015032960B1 (pt)	2013-07-04	2021-01-05	F. Hoffmann-La Roche Ag	imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
ES2881306T3 (es)	2013-09-27	2021-11-29	Chugai Pharmaceutical Co Ltd	Método para la producción de heteromultímeros de polipéptidos
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
IL314925A (en)	2015-08-18	2024-10-01	Regeneron Pharma	Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
JP7219005B2 (ja)	2015-12-28	2023-02-07	中外製薬株式会社	Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
WO2017147169A1 (en)	2016-02-22	2017-08-31	Ohio State Innovation Foundation	Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11033496B2 (en)	2017-03-17	2021-06-15	The Regents Of The University Of Michigan	Nanoparticles for delivery of chemopreventive agents
KR20200132938A (ko)	2018-03-15	2020-11-25	추가이 세이야쿠 가부시키가이샤	지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
EP3917618A1 (en)	2019-01-31	2021-12-08	Sanofi Biotechnology	Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
US20220177978A1 (en)	2019-04-02	2022-06-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
EP3959240A1 (en)	2019-04-24	2022-03-02	Sanofi Biotechnology	Methods of diagnosis and treatment of rheumatoid arthritis
AU2020288561A1 (en)	2019-06-04	2021-12-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for treating pain in subjects with rheumatoid arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996018648A1 (en) *	1994-12-14	1996-06-20	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Superagonists and antagonists of h il-6, and 3d modelling method for their selection
EP0783893A1 (en) *	1994-10-07	1997-07-16	Chugai Seiyaku Kabushiki Kaisha	Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
WO1998013383A1 (en) *	1996-09-24	1998-04-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
WO1999048523A2 (en) *	1998-03-26	1999-09-30	Glaxo Group Limited	Antagonists of the inflammatory mediator oncostatin m (osm)

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58201994A (ja)	1982-05-21	1983-11-25	Hideaki Hagiwara	抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5171840A (en)	1988-01-22	1992-12-15	Tadamitsu Kishimoto	Receptor protein for human B cell stimulatory factor-2
US6428979B1 (en)	1988-01-22	2002-08-06	Tadamitsu Kishimoto	Receptor protein for human B cell stimulatory factor-2
US5670373A (en) *	1988-01-22	1997-09-23	Kishimoto; Tadamitsu	Antibody to human interleukin-6 receptor
JP2914672B2 (ja)	1989-01-17	1999-07-05	中外製薬株式会社	Ｂｓｆ▲下２▼アンタゴニスト
US5216128A (en)	1989-06-01	1993-06-01	Yeda Research And Development Co., Ltd.	IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
DE69029015T2 (de)	1989-07-20	1998-01-22	Tadamitsu Kishimoto	Antikörper gegen menschlichen Interleukin-6-Rezeptor
JP2898064B2 (ja)	1989-08-03	1999-05-31	忠三岸本	ヒトｇｐ１３０蛋白質
JPH03155795A (ja)	1989-11-13	1991-07-03	Chuzo Kishimoto	マウス・インターロイキン―６レセプター蛋白質
JP2898040B2 (ja)	1990-01-26	1999-05-31	忠三岸本	ｇｐ１３０蛋白質に対する抗体
US5210075A (en)	1990-02-16	1993-05-11	Tanabe Seiyaku Co., Ltd.	Interleukin 6 antagonist peptides
AU665190B2 (en)	1990-07-10	1995-12-21	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
KR100272077B1 (ko)	1990-08-29	2000-11-15	젠팜인터내셔날,인코포레이티드	이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5795965A (en)	1991-04-25	1998-08-18	Chugai Seiyaku Kabushiki Kaisha	Reshaped human to human interleukin-6 receptor
JP3540315B2 (ja)	1991-09-23	2004-07-07	メディカルリサーチカウンシル	キメラ抗体の製造−組合せアプローチ
ATE408012T1 (de)	1991-12-02	2008-09-15	Medical Res Council	Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en)	1992-03-24	1993-09-30	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
WO1994002602A1 (en)	1992-07-24	1994-02-03	Cell Genesys, Inc.	Generation of xenogeneic antibodies
FR2694767B1 (fr)	1992-08-13	1994-10-21	Innotherapie Lab Sa	Anticorps monoclonaux anti-IL6R, et leurs applications.
US5648267A (en)	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en)	1993-04-26	1994-11-21	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
US5888510A (en) *	1993-07-21	1999-03-30	Chugai Seiyaku Kabushiki Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1995009873A1 (en)	1993-10-06	1995-04-13	Board Of Regents, The University Of Texas System	A monoclonal anti-human il-6 receptor antibody
WO1995015388A1 (en)	1993-12-03	1995-06-08	Medical Research Council	Recombinant binding proteins and peptides
JPH07324097A (ja)	1994-05-30	1995-12-12	Daicel Chem Ind Ltd	インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
US8017121B2 (en)	1994-06-30	2011-09-13	Chugai Seiyaku Kabushika Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO1996012503A1 (en)	1994-10-21	1996-05-02	Chugai Seiyaku Kabushiki Kaisha	Remedy for diseases caused by il-6 production
IT1274350B (it)	1994-12-06	1997-07-17	Angeletti P Ist Richerche Bio	Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
CN1075387C (zh)	1994-12-29	2001-11-28	中外制药株式会社	含有il－6拮抗剂的抗肿瘤剂的作用增强剂
CA2211578C (en)	1995-02-13	2010-09-21	Chugai Seiyaku Kabushiki Kaisha	Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
WO1996030394A1 (en)	1995-03-31	1996-10-03	Jakob Bohr	Method for protein folding
FR2733250B1 (fr)	1995-04-21	1997-07-04	Diaclone	Anticorps monoclonaux anti-gp130, et leurs utilisations
JP4312259B2 (ja)	1995-04-27	2009-08-12	アムジェンフレモントインク．	免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JPH08311098A (ja)	1995-05-22	1996-11-26	Daicel Chem Ind Ltd	新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US5571513A (en)	1995-05-31	1996-11-05	The Board Of Regents Of The University Of Oklahoma	Anti-gp130 monoclonal antibodies
ES2263178T3 (es)	1996-06-27	2006-12-01	Chugai Seiyaku Kabushiki Kaisha	Remedios para mieloma para ser utilizados junto con agentes antitumorales de mostaza nitrogenada.
AU736282B2 (en)	1997-03-21	2001-07-26	Chugai Seiyaku Kabushiki Kaisha	A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US20020187150A1 (en)	1997-08-15	2002-12-12	Chugai Seiyaku Kabushiki Kaisha	Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1074268E (pt)	1998-03-17	2008-02-28	Chugai Pharmaceutical Co Ltd	Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
US6537782B1 (en)	1998-06-01	2003-03-25	Chugai Seiyaku Kabushiki Kaisha	Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en)	1998-07-10	2002-06-18	Chugai Seiyaku Kabushiki Kaisha	Serum-free medium for culturing animal cells
PT1108435E (pt)	1998-08-24	2007-04-30	Chugai Pharmaceutical Co Ltd	Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo
AU2001278716A1 (en)	2000-08-10	2002-02-25	Chugai Seiyaku Kabushiki Kaisha	Method of inhibiting antibody-containing solution from coagulating or becoming turbid
WO2002013860A1 (en)	2000-08-11	2002-02-21	Chugai Seiyaku Kabushiki Kaisha	Stabilized antibody-containing preparations
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
IL155002A0 (en)	2000-10-12	2003-10-31	Genentech Inc	Reduced-viscosity concentrated protein formulations
WO2002034292A1 (fr)	2000-10-25	2002-05-02	Chugai Seiyaku Kabushiki Kaisha	Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002036164A1 (en)	2000-10-27	2002-05-10	Chugai Seiyaku Kabushiki Kaisha	Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
JP4889187B2 (ja)	2000-10-27	2012-03-07	中外製薬株式会社	Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
WO2002072615A1 (en)	2001-03-09	2002-09-19	Chugai Seiyaku Kabushiki Kaisha	Method of purifying protein
UA80091C2 (en)	2001-04-02	2007-08-27	Chugai Pharmaceutical Co Ltd	Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003068259A1 (fr)	2002-02-14	2003-08-21	Chugai Seiyaku Kabushiki Kaisha	Produits pharmaceutiques en solution contenant des anticorps
MXPA04009243A (es)	2002-04-12	2005-06-08	Pfizer	Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
JP3822137B2 (ja)	2002-05-20	2006-09-13	中外製薬株式会社	動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
SI1561756T1 (sl)	2002-09-11	2016-02-29	Chugai Seiyaku Kabushiki Kaisha	Postopek čiščenja proteinov
DE10255508A1 (de)	2002-11-27	2004-06-17	Forschungszentrum Jülich GmbH	Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
KR101142624B1 (ko)	2003-02-24	2012-06-15	추가이 세이야쿠 가부시키가이샤	인터루킨-6 길항제를 함유하는 척수손상 치료제
US20050158303A1 (en)	2003-04-04	2005-07-21	Genentech, Inc.	Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
DK1610820T4 (da)	2003-04-04	2013-11-04	Genentech Inc	Høj-koncentration antistof- og proteinformuleringer
GB2401040A (en)	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
EP1690550B1 (en)	2003-10-17	2012-08-08	Chugai Seiyaku Kabushiki Kaisha	Therapeutic agent for mesothelioma
AR048210A1 (es)	2003-12-19	2006-04-12	Chugai Pharmaceutical Co Ltd	Un agente preventivo para la vasculitis.
US8617550B2 (en)	2003-12-19	2013-12-31	Chugai Seiyaku Kabushiki Kaisha	Treatment of vasculitis with IL-6 antagonist
AR048335A1 (es)	2004-03-24	2006-04-19	Chugai Pharmaceutical Co Ltd	Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
JPWO2005090405A1 (ja)	2004-03-24	2008-04-17	中外製薬株式会社	インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
EP2843040A1 (en)	2005-01-05	2015-03-04	Chugai Seiyaku Kabushiki Kaisha	Cell culture method and utilization of the same
WO2007043641A1 (ja)	2005-10-14	2007-04-19	Fukuoka University	膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt)	2005-10-21	2021-05-25	Chugai Pharmaceutical Co Ltd	uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es)	2005-11-15	2007-12-05	Nat Hospital Organization	Agentes para suprimir la induccion de linfocitos t citotoxicos
KR20080084818A (ko)	2005-11-25	2008-09-19	각고호우징 게이오기주크	전립선암 치료제
WO2007074880A1 (ja)	2005-12-28	2007-07-05	Chugai Seiyaku Kabushiki Kaisha	抗体含有安定化製剤
AU2007208678B2 (en)	2006-01-27	2013-01-10	Chugai Seiyaku Kabushiki Kaisha	Therapeutic agents for diseases involving choroidal neovascularization
EP1996943B1 (en)	2006-03-09	2014-06-25	F.Hoffmann-La Roche Ag	Anti-drug antibody assay
WO2007116962A1 (ja)	2006-04-07	2007-10-18	Osaka University	筋再生促進剤
JP5330829B2 (ja)	2006-08-04	2013-10-30	憲弘西本	関節リウマチ患者の治療予後予測方法
JP2010095445A (ja)	2006-12-27	2010-04-30	Tokyo Medical & Dental Univ	Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CN101646459B (zh)	2007-01-23	2014-02-12	国立大学法人信州大学	慢性排斥反应抑制剂
JP5424330B2 (ja)	2007-07-26	2014-02-26	国立大学法人大阪大学	インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
RU2505603C2 (ru)	2007-09-26	2014-01-27	Чугаи Сейяку Кабусики Кайся	Антитело против рецептора il-6
KR101601986B1 (ko)	2007-10-02	2016-03-17	추가이 세이야쿠 가부시키가이샤	인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
JP2009092508A (ja)	2007-10-09	2009-04-30	Norihiro Nishimoto	リウマチ治療剤の効果の予測方法
CA2709127C (en)	2007-12-15	2013-11-12	F. Hoffmann-La Roche Ag	Distinguishing assay
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5544290B2 (ja)	2008-06-05	2014-07-09	独立行政法人国立がん研究センター	神経浸潤抑制剤
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
MY161541A (en)	2009-07-31	2017-04-28	Shin Maeda	Cancer metastasis inhibitor
HUE033758T2 (en)	2009-10-26	2017-12-28	Hoffmann La Roche	A method for producing glycosylated immunoglobulin
WO2011128096A1 (en)	2010-04-16	2011-10-20	Roche Diagnostics Gmbh	Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
EP2578233B1 (en)	2010-05-28	2017-04-26	National Cancer Center	Therapeutic agent for pancreatic cancer
HUE060454T2 (hu)	2010-05-28	2023-03-28	Chugai Pharmaceutical Co Ltd	Daganatellenes T-sejt-választ fokozó szer
EP2576824A2 (en)	2010-06-07	2013-04-10	Roche Diagnostics GmbH	Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
EP4029881A1 (en)	2010-11-08	2022-07-20	F. Hoffmann-La Roche AG	Subcutaneously administered anti-il-6 receptor antibody
CA2847302C (en)	2011-09-01	2021-02-16	Chugai Seiyaku Kabushiki Kaisha	Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration

2002
- 2002-02-04 UA UA2003109818A patent/UA80091C2/uk unknown
- 2002-04-02 RU RU2008102979/15A patent/RU2541165C2/ru active
- 2002-04-02 NZ NZ528479A patent/NZ528479A/en not_active IP Right Cessation
- 2002-04-02 RU RU2003132066/15A patent/RU2361613C2/ru active
- 2002-04-02 US US10/473,165 patent/US20040115197A1/en not_active Abandoned
- 2002-04-02 IL IL15807902A patent/IL158079A0/xx unknown
- 2002-04-02 HU HU0303952A patent/HU230197B1/hu unknown
- 2002-04-02 EP EP08010046A patent/EP1972638A1/en not_active Ceased
- 2002-04-02 JP JP2002579008A patent/JP3702274B2/ja not_active Expired - Lifetime
- 2002-04-02 BR BR0208636-0A patent/BR0208636A/pt not_active Application Discontinuation
- 2002-04-02 EP EP02708772A patent/EP1374900A4/en not_active Ceased
- 2002-04-02 WO PCT/JP2002/003312 patent/WO2002080969A1/ja not_active Ceased
- 2002-04-02 KR KR1020087005693A patent/KR100842132B1/ko not_active Expired - Lifetime
- 2002-04-02 EP EP10011862A patent/EP2298812A3/en not_active Withdrawn
- 2002-04-02 KR KR1020037012661A patent/KR100842133B1/ko not_active Expired - Lifetime
- 2002-04-02 CA CA2443294A patent/CA2443294C/en not_active Expired - Lifetime
- 2002-04-02 AU AU2002243032A patent/AU2002243032B2/en not_active Expired
- 2002-04-02 PL PL365339A patent/PL216534B1/pl unknown
- 2002-04-02 EP EP19196253.9A patent/EP3640261A1/en not_active Withdrawn
- 2002-04-02 MX MXPA03008955A patent/MXPA03008955A/es active IP Right Grant
- 2002-04-02 CN CNB028077849A patent/CN100562339C/zh not_active Expired - Lifetime
2003
- 2003-09-24 IL IL158079A patent/IL158079A/en active IP Right Grant
- 2003-10-01 NO NO20034388A patent/NO20034388L/no not_active Application Discontinuation
2005
- 2005-02-18 JP JP2005043099A patent/JP3702289B2/ja not_active Expired - Lifetime
- 2005-02-18 JP JP2005042930A patent/JP2005139205A/ja not_active Withdrawn
2007
- 2007-02-09 US US11/704,233 patent/US7955598B2/en not_active Expired - Lifetime
- 2007-11-25 IL IL187604A patent/IL187604A/en active IP Right Grant
2008
- 2008-11-14 JP JP2008292518A patent/JP2009073857A/ja not_active Withdrawn
2011
- 2011-04-28 US US13/064,953 patent/US9255145B2/en not_active Expired - Fee Related
2012
- 2012-04-12 JP JP2012091380A patent/JP5591279B2/ja not_active Expired - Lifetime
2016
- 2016-01-04 US US14/986,884 patent/US20160194401A1/en not_active Abandoned
2018
- 2018-04-06 US US15/946,866 patent/US20180222988A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0783893A1 (en) *	1994-10-07	1997-07-16	Chugai Seiyaku Kabushiki Kaisha	Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
WO1996018648A1 (en) *	1994-12-14	1996-06-20	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Superagonists and antagonists of h il-6, and 3d modelling method for their selection
WO1998013383A1 (en) *	1996-09-24	1998-04-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
WO1999048523A2 (en) *	1998-03-26	1999-09-30	Glaxo Group Limited	Antagonists of the inflammatory mediator oncostatin m (osm)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DANIEL WENDLING ET AL.: "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody", THE JOURNAL OF RHEUMATOLOGY, vol. 20, 1993, pages 259 - 262, XP002917899 *
G. CARROLL ET AL.: "Antagonism of the IL-6 cytokine subfamily- a potential strategy for more effective therapy in rheumatoid arthritis", INFLAMM. RES., vol. 47, 1998, pages 1 - 7, XP002115636 *
LEPORE L. ET AL.: "Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluis of patients with juvenile chronic arthritis", CLIN. EXP. THEUMATOL., vol. 12, no. 5, 1994, pages 561 - 565, XP002953582 *
M.J. ELLIOTT ET AL.: "Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2)", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 36, 1997, pages 589 - 593, XP002953580 *
OEN K. ET AL.: "Interleukin 6 and autoantibodies in juvenile rheumatoid arthritis", J. RHEUMATOL., vol. 20, no. 11, 1993, pages 1949 - 1956, XP002953581 *
ROONEY M. ET AL.: "Inflammatory cytokine responses in juvenile chronic arthritis", BR. J. RHEUMATO., vol. 34, no. 5, 1995, pages 454 - 460, XP002953583 *
See also references of EP1374900A4 *
TAKE H. ET AL.: "Successful treatment with aurranofin in a patient with elderly-onset Still's disease", J. MED., vol. 25, no. 6, 1994, pages 393 - 397, XP002953584 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4098279A1 (en)	2003-04-28	2022-12-07	Chugai Seiyaku Kabushiki Kaisha	Methods for treating interleukin-6 related diseases
EP3903819A1 (en)	2003-04-28	2021-11-03	Chugai Seiyaku Kabushiki Kaisha	Methods for treating interleukin-6 related diseases
EP3167901A1 (en)	2003-04-28	2017-05-17	Chugai Seiyaku Kabushiki Kaisha	Methods for treating interleukin-6 related diseases
EP2368577A2 (en)	2003-04-28	2011-09-28	Chugai Seiyaku Kabushiki Kaisha	Methods for treating interleukin-6 related diseases
JP2007525524A (ja) *	2004-02-26	2007-09-06	ベイラー・リサーチ・インスチチユート	関節炎の全身処置のための組成物および方法
JP2012162552A (ja) *	2004-02-26	2012-08-30	Baylor Research Inst	関節炎の全身処置のための組成物および方法
US8945558B2 (en)	2005-10-21	2015-02-03	Chugai Seiyaku Kabushiki Kaisha	Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US12473375B2 (en)	2006-03-31	2025-11-18	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
US11046784B2 (en)	2006-03-31	2021-06-29	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
US9260516B2 (en)	2006-04-07	2016-02-16	Osaka University	Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US7919095B2 (en)	2006-08-03	2011-04-05	Vaccinex, Inc.	Anti-IL-6 monoclonal antibodies
WO2008078715A1 (ja) *	2006-12-27	2008-07-03	Chugai Seiyaku Kabushiki Kaisha	Ｉｌ－６アンタゴニストを有効成分とする炎症性筋疾患治療剤
US9725514B2 (en)	2007-01-23	2017-08-08	Shinshu University	Chronic rejection inhibitor
US12116414B2 (en)	2007-09-26	2024-10-15	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en)	2007-09-26	2024-10-22	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11332533B2 (en)	2007-09-26	2022-05-17	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
US11248053B2 (en)	2007-09-26	2022-02-15	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11371039B2 (en)	2008-04-11	2022-06-28	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en)	2008-04-11	2022-06-14	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US10717781B2 (en)	2008-06-05	2020-07-21	National Cancer Center	Neuroinvasion inhibitor
US10662245B2 (en)	2008-09-26	2020-05-26	Chugai Seiyaku Kabushiki Kaisha	Methods of reducing IL-6 activity for disease treatment
EP4115906A1 (en)	2010-05-28	2023-01-11	Chugai Seiyaku Kabushiki Kaisha	Antitumor t cell response enhancer
WO2011149051A1 (ja)	2010-05-28	2011-12-01	中外製薬株式会社	抗腫瘍t細胞応答増強剤
US11285208B2 (en)	2010-05-28	2022-03-29	National Cancer Center	Therapeutic agents for pancreatic cancer
US9539322B2 (en)	2010-05-28	2017-01-10	National University Corporation Hokkaido University	Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
WO2011149046A1 (ja)	2010-05-28	2011-12-01	独立行政法人国立がん研究センター	膵癌治療剤
US11891434B2 (en)	2010-11-30	2024-02-06	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2013176471A1 (ko)	2012-05-21	2013-11-28	한국생명공학연구원	곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
US10782290B2 (en)	2013-06-11	2020-09-22	National Center Of Neurology And Psychiatry	Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
CN103739669B (zh) *	2013-12-31	2015-08-26	浙江元太生物科技有限公司	一种抑制白介素-6多肽及其应用
CN103739669A (zh) *	2013-12-31	2014-04-23	罗瑞雪	一种抑制白介素-6多肽及其应用
US10774148B2 (en)	2015-02-27	2020-09-15	Chugai Seiyaku Kabushiki Kaisha	Composition for treating IL-6-related diseases
US10697883B2 (en)	2015-05-19	2020-06-30	National Center Of Neurology And Psychiatry	Method for determining application of therapy to multiple sclerosis (MS) patient
US11174317B2 (en)	2015-06-04	2021-11-16	National Center Of Neurology And Psychiatry	Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en)	2017-10-20	2023-07-04	Hyogo College Of Medicine	Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Also Published As

Publication number	Publication date
HUP0303952A2 (hu)	2004-03-01
KR20080027401A (ko)	2008-03-26
NZ528479A (en)	2005-08-26
US20160194401A1 (en)	2016-07-07
US20070148169A1 (en)	2007-06-28
JP5591279B2 (ja)	2014-09-17
US9255145B2 (en)	2016-02-09
JP2012140464A (ja)	2012-07-26
BR0208636A (pt)	2004-03-09
RU2361613C2 (ru)	2009-07-20
US20180222988A1 (en)	2018-08-09
US20040115197A1 (en)	2004-06-17
EP2298812A3 (en)	2011-07-13
EP1972638A1 (en)	2008-09-24
CN100562339C (zh)	2009-11-25
CA2443294C (en)	2013-09-24
RU2008102979A (ru)	2009-08-10
MXPA03008955A (es)	2004-02-18
PL365339A1 (en)	2004-12-27
EP1374900A1 (en)	2004-01-02
JPWO2002080969A1 (ja)	2004-07-29
UA80091C2 (en)	2007-08-27
NO20034388L (no)	2003-10-21
HUP0303952A3 (en)	2012-09-28
RU2541165C2 (ru)	2015-02-10
CA2443294A1 (en)	2002-10-17
US7955598B2 (en)	2011-06-07
HK1062408A1 (zh)	2004-11-05
KR20030087655A (ko)	2003-11-14
EP3640261A1 (en)	2020-04-22
JP2005206604A (ja)	2005-08-04
JP2009073857A (ja)	2009-04-09
RU2003132066A (ru)	2005-04-10
IL158079A (en)	2012-01-31
EP1374900A4 (en)	2004-07-21
CN1499983A (zh)	2004-05-26
KR100842132B1 (ko)	2008-06-27
IL187604A (en)	2011-12-29
KR100842133B1 (ko)	2008-06-27
JP3702274B2 (ja)	2005-10-05
EP2298812A2 (en)	2011-03-23
IL158079A0 (en)	2004-03-28
AU2002243032B2 (en)	2008-01-31
US20110206664A1 (en)	2011-08-25
IL187604A0 (en)	2009-02-11
JP2005139205A (ja)	2005-06-02
PL216534B1 (pl)	2014-04-30
JP3702289B2 (ja)	2005-10-05
NO20034388D0 (no)	2003-10-01
HU230197B1 (hu)	2015-10-28

Publication	Publication Date	Title
WO2002080969A1 (en)	2002-10-17	Remedies for infant chronic arthritis-relating diseases
AU2000279625A1 (en)	2002-05-15	Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU1095202A (en)	2002-05-06	Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
AU2002210952A1 (en)	2002-07-11	Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
CA2458067A1 (en)	2003-05-01	Use of flibanserin in the treatment of sexual disorders
HUP0101694A3 (en)	2003-08-28	Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists
PT1441705E (pt)	2014-10-20	Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos
EP1425277B8 (en)	2009-04-01	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
MXPA03007215A (es)	2003-12-04	Formulaciones farmaceuticas.
MXPA03006884A (es)	2003-11-13	Formulacion farmaceutica.
WO2005045689A8 (en)	2007-06-28	Methods and systems for network coordination
WO2003037860A3 (en)	2004-03-25	Purine analogs having hsp90-inhibiting activity
AU2002318759A1 (en)	2003-05-29	Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
AU2002243032A1 (en)	2003-04-10	Remdies for infant chronic arthritis-relating diseases
MXPA03007641A (es)	2003-12-04	Formulacion farmaceutica.
HUP0400155A3 (en)	2007-05-02	N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
EP1406493A4 (en)	2006-06-14	ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
ZA200402729B (en)	2005-01-13	Pharmaceutical formulation comprising (R) -bicalutamide.
IL159478A0 (en)	2004-06-01	Remedies for eosinophilic diseases
ITMI20001848A0 (it)	2000-08-08	Faramaci per l'incontinenza.
AU2001258442A1 (en)	2001-11-20	Drug delivery device, especially for the delivery of levonorgestrel
EP1273301A3 (en)	2003-04-09	Pharmaceutical preparations based on active ingredients susceptible to illict administration
GB0128071D0 (en)	2002-01-16	Medicament
Torabi	2001	The woman from the perspective of Revelation
AU2002324469A1 (en)	2003-03-10	Substituted-heteroaryl-7-aza(2.2.1)bicycloheptanes for the treatment of disease

Legal Events

Date	Code	Title	Description
2002-10-17	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
2002-10-17	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2002-11-14	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2002-12-11	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-05-28	WWE	Wipo information: entry into national phase	Ref document number: 2002579008 Country of ref document: JP
2003-09-23	WWE	Wipo information: entry into national phase	Ref document number: 2002243032 Country of ref document: AU
2003-09-24	WWE	Wipo information: entry into national phase	Ref document number: 158079 Country of ref document: IL
2003-09-25	WWE	Wipo information: entry into national phase	Ref document number: 528479 Country of ref document: NZ
2003-09-27	WWE	Wipo information: entry into national phase	Ref document number: 1020037012661 Country of ref document: KR
2003-09-29	WWE	Wipo information: entry into national phase	Ref document number: 10473165 Country of ref document: US
2003-09-30	WWE	Wipo information: entry into national phase	Ref document number: 028077849 Country of ref document: CN
2003-10-01	REEP	Request for entry into the european phase	Ref document number: 2002708772 Country of ref document: EP
2003-10-01	WWE	Wipo information: entry into national phase	Ref document number: PA/a/2003/008955 Country of ref document: MX Ref document number: 2002708772 Country of ref document: EP Ref document number: 2443294 Country of ref document: CA
2004-01-02	WWP	Wipo information: published in national office	Ref document number: 2002708772 Country of ref document: EP
2004-02-19	REG	Reference to national code	Ref country code: DE Ref legal event code: 8642
2005-08-26	WWP	Wipo information: published in national office	Ref document number: 528479 Country of ref document: NZ
2005-12-08	WWG	Wipo information: grant in national office	Ref document number: 528479 Country of ref document: NZ
2007-11-25	WWE	Wipo information: entry into national phase	Ref document number: 187604 Country of ref document: IL